- Home
- AKBA vs DADA Comparison
AKBA vs DADA Comparison
Compare AKBA & DADA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- DADA
- Stock Information
- Founded
- AKBA 2007
- DADA 2014
- Country
- AKBA United States
- DADA China
- Employees
- AKBA N/A
- DADA N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- DADA Computer Software: Programming Data Processing
- Sector
- AKBA Health Care
- DADA Technology
- Exchange
- AKBA Nasdaq
- DADA Nasdaq
- Market Cap
- AKBA 336.2M
- DADA 379.3M
- IPO Year
- AKBA 2014
- DADA 2020
- Fundamental
- Price
- AKBA $1.83
- DADA $1.35
- Analyst Decision
- AKBA Strong Buy
- DADA Buy
- Analyst Count
- AKBA 1
- DADA 6
- Target Price
- AKBA $7.50
- DADA $2.73
- AVG Volume (30 Days)
- AKBA 2.4M
- DADA 941.1K
- Earning Date
- AKBA 11-07-2024
- DADA 11-13-2024
- Dividend Yield
- AKBA N/A
- DADA N/A
- EPS Growth
- AKBA N/A
- DADA N/A
- EPS
- AKBA N/A
- DADA N/A
- Revenue
- AKBA $169,879,000.00
- DADA $1,423,236,152.00
- Revenue This Year
- AKBA N/A
- DADA N/A
- Revenue Next Year
- AKBA $30.85
- DADA $11.53
- P/E Ratio
- AKBA N/A
- DADA N/A
- Revenue Growth
- AKBA N/A
- DADA N/A
- 52 Week Low
- AKBA $0.80
- DADA $1.04
- 52 Week High
- AKBA $2.48
- DADA $3.67
- Technical
- Relative Strength Index (RSI)
- AKBA 46.55
- DADA 41.13
- Support Level
- AKBA $1.74
- DADA $1.40
- Resistance Level
- AKBA $1.90
- DADA $1.50
- Average True Range (ATR)
- AKBA 0.09
- DADA 0.08
- MACD
- AKBA -0.03
- DADA -0.00
- Stochastic Oscillator
- AKBA 20.93
- DADA 6.98
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About DADA Dada Nexus Limited
Dada Nexus is a leading crowdsourced delivery service in China. The company has two core businesses, Dada Now, which is an on-demand delivery platform that provides last-mile and intracity services; and JD Daojia, or JDDJ, which is an online on-demand retail platform that connects consumers to merchants with its delivery capabilities. As of 2022, Dada Now accounted for 34% of revenue while JDDJ accounted for the rest. JDDJ and Dada Nexus merged in 2016, where JD.com received 47.4% ownership of the merged entity in exchange for its JDDJ business. As of June 2023, JD.com and Walmart Inc own 53.9% and 9.3% of Dada Nexus, respectively. Dada Nexus competes with other logistics companies such as SF Intra-City, with Didi in its delivery business, and with Meituan in its on-demand retail segment.